Small cell lung cancer (SCLC)
Conditions
Brief summary
Overall Survival is defined as the length of time from start of treatment (tarlatamab or Standard Of Care) for the disease until death, due to any cause
Detailed description
The length of time the participants are grouped to receive either tarlatamab or Standard Of Care by chance until the disease has progressed or resulted in death, Change from Baseline PROs assessed 6-weekly over time to 18 weeks for Chest Pain, cough as measured by EORTC-QLQ-LC13; Tightening in the chest as measured by EORTC-QLQ-C30 and EORTC-QLQ-LC13; and Physical Function and Global Health Status of life as measured by EORTC-QLQ-C30
Interventions
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival is defined as the length of time from start of treatment (tarlatamab or Standard Of Care) for the disease until death, due to any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| The length of time the participants are grouped to receive either tarlatamab or Standard Of Care by chance until the disease has progressed or resulted in death, Change from Baseline PROs assessed 6-weekly over time to 18 weeks for Chest Pain, cough as measured by EORTC-QLQ-LC13; Tightening in the chest as measured by EORTC-QLQ-C30 and EORTC-QLQ-LC13; and Physical Function and Global Health Status of life as measured by EORTC-QLQ-C30 | — |
Countries
Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Spain
Outcome results
None listed